drugset / Trial / NCT05036291

A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

NCT05036291

Phase 1 Terminated 25 enrolled Ningbo Newbay Technology Development Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB004 Administered as Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors

Timeline

Start
2021-10-01
Primary completion
2025-09-24
Completion
2025-10-10

Drugs

EvaluationDrugModalityDoseRoute
Subject NB004 Unknown Oral
Background Sotorasib Small molecule